EECP, or enhanced external counterpulsation, is a noninvasive treatment that uses inflatable cuffs wrapped around your legs to boost blood flow to your heart. It’s primarily used for people with chronic chest pain (angina) who haven’t gotten enough relief from medications or surgery. A standard course involves 35 one-hour sessions, typically scheduled five days a week over seven weeks.
How EECP Works
During a session, you lie on a treatment bed with three sets of large pneumatic cuffs strapped around your calves, thighs, and buttocks. These cuffs are connected to a computer that monitors your heartbeat through an ECG. The timing is everything: the cuffs inflate sequentially, from calves up to buttocks, at the exact moment your heart relaxes between beats (diastole). This squeezes blood from your lower body back toward your heart and into your coronary arteries, significantly increasing blood flow and pressure in those arteries during the filling phase.
Then, just as your heart contracts to pump (systole), all three cuffs deflate instantly. This rapid release reduces the resistance your heart has to pump against, effectively lightening its workload. The overall effect is similar to what an intra-aortic balloon pump does inside the body, but entirely from the outside. Beyond pushing blood back to the heart, the leg compression also increases the amount of blood returning through the veins, giving the heart more volume to work with on each beat.
What EECP Does Inside Your Blood Vessels
The repeated surges of blood flow during EECP create something called shear stress on the walls of your blood vessels. This mechanical force triggers a cascade of beneficial responses. Your blood vessels produce more nitric oxide, a molecule that relaxes artery walls and improves their ability to expand. Over the course of treatment, this can reduce arterial stiffness and improve overall vascular function.
EECP also appears to stimulate the growth of new small blood vessels, a process called angiogenesis. Research published in Frontiers in Cardiovascular Medicine found that patients receiving EECP maintained higher levels of key growth factors involved in blood vessel formation compared to a sham-treated control group. These new collateral vessels can create natural bypasses around narrowed or blocked arteries, which helps explain why benefits often persist well after the treatment course ends.
Who EECP Is Used For
The primary use is chronic stable angina that hasn’t responded adequately to medications, stenting, or bypass surgery. Medicare covers EECP for beneficiaries with stable angina that is refractory to other treatments, classifying it as “reasonable and necessary” for this group. It’s also been studied in patients with heart failure caused by reduced blood flow to the heart.
About 70% of angina patients experience a meaningful reduction in symptom severity after completing a full course. Roughly a third of patients improve by two or more functional classes, meaning someone who previously couldn’t walk a block without chest pain might be able to climb stairs or exercise moderately. A registry study tracking patients with both refractory angina and reduced heart function found that 55% maintained their improvement at the two-year mark, with low rates of major cardiac events during that period.
Effects on Heart Failure
For patients with heart failure due to coronary artery disease, the picture is more nuanced. The treatment consistently improves exercise tolerance: patients in EECP groups show significantly longer total exercise times and better performance on six-minute walk tests, with those gains lasting up to six months after treatment. Patients also tend to move to a lower, less symptomatic heart failure class.
Whether EECP improves the heart’s pumping efficiency is less clear. Multiple studies have produced mixed results on ejection fraction, the standard measure of how well the heart contracts. Some smaller studies found significant improvement, particularly in patients who started with very low pumping function (below 40%), while larger trials found no meaningful change. The heart’s ability to relax and fill with blood (diastolic function) does consistently improve, which matters because stiffness during filling contributes heavily to symptoms like shortness of breath and fatigue.
What a Treatment Course Looks Like
A full course is 35 sessions, each lasting one hour, done Monday through Friday for seven weeks. You remain fully clothed (usually in thin pants or leggings) and lie on the treatment bed while the cuffs cycle in rhythm with your heartbeat. Most people read, watch TV, or nap during sessions. The sensation is a firm, rhythmic squeezing of the legs, similar to a deep compression massage.
Side effects are minimal. Occasional mild skin irritation can occur where the cuffs press against the body, but bruising and pressure sores are rare. There’s no recovery time after each session, and most people return to their normal activities immediately.
Who Should Not Have EECP
Several conditions make EECP unsafe. The treatment compresses veins forcefully, so anyone with a blood clot in their leg veins (deep vein thrombosis) or active inflammation of a vein cannot undergo it. Other contraindications include:
- Aortic or brain aneurysm: the pressure changes could be dangerous
- Moderate to severe aortic valve leakage: counterpulsation worsens regurgitation
- Uncontrolled high blood pressure above 180/110
- Decompensated heart failure: when the heart is acutely overwhelmed and unable to keep up
- Bleeding disorders
- Severe pulmonary hypertension
- Irregular heart rhythms that would prevent the machine from syncing cuff inflation to the heartbeat
- Active infection in the legs
How Long Benefits Last
One of EECP’s advantages over a single procedure is that its effects appear to build gradually and persist. The vascular remodeling, improved endothelial function, and new collateral blood vessel growth don’t disappear when sessions end. Data from the International EECP Patient Registry show that reduced angina and improved quality of life hold at two years for more than half of patients, with only modest rates of needing a repeat course. Some patients do return for additional treatment cycles if symptoms eventually recur, and repeat courses follow the same 35-session protocol.